Vupanorsen - Ionis Pharmaceuticals/Pfizer
Alternative Names: AKCEA ANGPTL3 LRx; IONIS ANGPTL3 LRx; ISIS 703802 salt; ISIS-703802; PF 07285557; Vupanorsen sodiumLatest Information Update: 28 Sep 2023
At a glance
- Originator Ionis Pharmaceuticals
- Developer Akcea Therapeutics; Ionis Pharmaceuticals; Pfizer
- Class Antihyperglycaemics; Antihyperlipidaemics; Antisense oligonucleotides; Hepatoprotectants
- Mechanism of Action ANGPTL3 protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dyslipidaemias; Familial partial lipodystrophy; Hyperlipoproteinaemia type I; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Phase I/II Hyperlipoproteinaemia type IIa
- Discontinued Hypertriglyceridaemia
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Hyperlipoproteinaemia-type-I(In the elderly, In volunteers, In adults) in Japan (SC, Injection)
- 08 Feb 2022 Discontinued - Phase-I for Hypertriglyceridaemia (In volunteers) in China (SC)
- 08 Feb 2022 Discontinued - Phase-II for Hypertriglyceridaemia in USA, Canada (SC)